Vaxart, INC Form 4 insider transactions

Kevin Finney, a Director of Vaxart, Inc., reported multiple transactions in common stock on July 16, 2026.

James B Breitmeyer, a Director of Vaxart, Inc., reported multiple transactions in common stock on July 16, 2026.

Elaine J Heron, a Director of Vaxart, Inc., reported multiple transactions in common stock on July 16, 2026.

W. Mark Watson, a Director of Vaxart, Inc., reported multiple transactions in common stock on July 16, 2026.

David E. Wheadon, a Director of Vaxart, Inc., reported multiple transactions in common stock on July 16, 2026.

Vaxart, Inc. reports that Director W. Mark Watson acquired 10,000 shares of common stock on May 22, 2026.

Vaxart CFO Jeroen Nicolaas Grasman disposed of 31,395 shares to satisfy tax obligations related to RSU vesting.

Director James B. Breitmeyer acquired 78,800 shares and 157,400 stock options as part of a board compensation grant.

Vaxart's SVP and Chief Scientific Officer, Sean Tucker, reported a disposition of 3,924 common shares for tax withholding purposes related to vested RSUs.

Vaxart's Chief Medical Officer, James F. Cummings, disposed of 3,292 common shares to cover tax obligations related to vested restricted stock units.

Vaxart's SVP, General Counsel, Edward B. Berg, reported the withholding of 36,418 shares for tax obligations related to vested RSUs.

Vaxart's Chief Medical Officer, James F. Cummings, reported the disposition of 30,551 shares of common stock to cover tax liabilities related to RSU vesting.

Vaxart CEO Steven Lo reported a disposition of 126,028 shares of common stock to cover tax obligations related to vested restricted stock units.

Vaxart's Chief Scientific Officer, Sean Tucker, reported the withholding of 36,418 common shares to cover tax obligations related to vested Restricted Stock Units.

Vaxart's SVP and General Counsel, Edward B. Berg, reported the withholding of 8,072 shares for tax obligations related to RSU vesting.

Vaxart's Chief Medical Officer reported a routine disposition of shares to cover tax obligations related to RSU vesting.

Vaxart's President and CEO, Steven Lo, disposed of 22,425 common shares to cover tax obligations related to vested restricted stock units.

Vaxart's Chief Scientific Officer, Sean Tucker, disposed of 8,072 common shares to cover tax obligations related to vested restricted stock units.

Vaxart's President and CEO, Steven Lo, acquired 846,500 shares of common stock and 1,543,000 stock options through equity grants, increasing his beneficial ownership.

Vaxart's Chief Scientific Officer, Sean Tucker, increased his direct beneficial ownership through the vesting of restricted stock units and the grant of new stock options.

Vaxart's Chief Financial Officer, Jeroen Nicolaas Grasman, was granted 227,000 restricted stock units and 455,000 stock options.

Vaxart's Chief Medical Officer, James F. Cummings, was granted 227,000 common shares and 455,000 stock options with specific vesting schedules.

Vaxart's SVP and General Counsel, Edward B. Berg, reported the acquisition of 115,000 common shares and 225,000 stock options.

Vaxart's Chief Medical Officer, James F. Cummings, reported a disposition of shares to cover tax obligations related to vested restricted stock units.

Vaxart's SVP and General Counsel, Edward B. Berg, disposed of 9,265 shares of common stock to cover tax obligations related to RSU vesting.

Vaxart's SVP and Chief Scientific Officer, Sean Tucker, reported the sale of 9,265 common shares to cover tax obligations related to vested restricted stock units.

Vaxart CEO Steven Lo reported the vesting of restricted stock units and subsequent tax-related share disposals, alongside new share acquisitions, impacting his beneficial ownership.

Vaxart Director W. Mark Watson acquired 20,000 shares of common stock for approximately $8,185, increasing his direct beneficial ownership to 124,125 shares.

Vaxart Director Elaine Heron reported the acquisition of 40,000 shares of common stock on November 17, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Vaxart Director Kevin Finney acquired over 150,000 shares of common stock in open market purchases during July and August 2025, increasing his direct beneficial ownership.